| Erin Lynn Brendle, NP | |
|
1900 S Main St, Findlay, OH 45840-1214 | |
| (419) 423-4500 | |
| Not Available |
| Full Name | Erin Lynn Brendle |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 3 Years |
| Location | 1900 S Main St, Findlay, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770220741 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VG0400X | Obstetrics & Gynecology - Gynecology | APRN.CNP.0031183 (Ohio) | Secondary |
| 363L00000X | Nurse Practitioner | APRN.CNP.0031183 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Blanchard Valley Hospital | Findlay, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Blanchard Valley Medical Practice Llc | 9234168147 | 68 |
News Archive
Experts in the U.S. say food allergies are on the rise and although strict avoidance is currently the only treatment, new effective therapies are currently being developed.
Patients who suffer heart attacks, or flare-ups of congestive heart failure, can be cared for in a variety of hospital locations. But a new study suggests that they'll fare worse in hospitals that rely heavily on their intensive care units to care for patients like them.
A study has found that a short course of intensive insulin treatment may delay the progression of the disease in people newly diagnosed with type 2 diabetes
Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.
› Verified 7 days ago
| Entity Name | Blanchard Valley Medical Practice Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962501627 PECOS PAC ID: 9234168147 Enrollment ID: O20050811000177 |
News Archive
Experts in the U.S. say food allergies are on the rise and although strict avoidance is currently the only treatment, new effective therapies are currently being developed.
Patients who suffer heart attacks, or flare-ups of congestive heart failure, can be cared for in a variety of hospital locations. But a new study suggests that they'll fare worse in hospitals that rely heavily on their intensive care units to care for patients like them.
A study has found that a short course of intensive insulin treatment may delay the progression of the disease in people newly diagnosed with type 2 diabetes
Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Erin Lynn Brendle, NP 9005 Township Road 108, New Riegel, OH 44853-9726 Ph: () - | Erin Lynn Brendle, NP 1900 S Main St, Findlay, OH 45840-1214 Ph: (419) 423-4500 |
News Archive
Experts in the U.S. say food allergies are on the rise and although strict avoidance is currently the only treatment, new effective therapies are currently being developed.
Patients who suffer heart attacks, or flare-ups of congestive heart failure, can be cared for in a variety of hospital locations. But a new study suggests that they'll fare worse in hospitals that rely heavily on their intensive care units to care for patients like them.
A study has found that a short course of intensive insulin treatment may delay the progression of the disease in people newly diagnosed with type 2 diabetes
Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.
› Verified 7 days ago